Loading…
NeuroPace, Inc. is projected to rise to $22.28 by 2027, a +30% move from its current price of $17.11. NPCE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $16.69 | $17.11 | $17.55 | +0.02% |
| Jul 14 | $16.51 | $17.12 | $17.74 | +0.04% |
| Jul 15 | $16.39 | $17.12 | $17.89 | +0.06% |
| Jul 16 | $16.28 | $17.12 | $18.01 | +0.09% |
| Jul 17 | $16.18 | $17.13 | $18.13 | +0.11% |
| Jul 18 | $16.10 | $17.13 | $18.23 | +0.13% |
| Jul 19 | $16.02 | $17.14 | $18.32 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.02 | $17.14 | $18.32 | +0.15% |
| Week 2 | $15.61 | $17.16 | $18.87 | +0.30% |
| Week 3 | $15.30 | $17.19 | $19.30 | +0.45% |
| Week 4 | $15.05 | $17.21 | $19.68 | +0.60% |
| Week 5 | $14.84 | $17.24 | $20.03 | +0.75% |
| Week 6 | $14.65 | $17.26 | $20.35 | +0.90% |
| Week 7 | $14.48 | $17.29 | $20.65 | +1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures.
NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace, Inc. (NPCE) is a healthcare company listed with a current price of $17.33 and a market capitalization of $590.84M. It holds a rank of 2897 among listed assets. The company focuses on medical devices for epilepsy treatment, with its RNS System designed to deliver real-time neuromodulation at seizure sources.
The current price and near-term outlook reflect a 30-day technical picture that blends bullish sentiment with defined support and resistance levels.
A major floor 25.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.2% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 13.5% above — clearing it would confirm fresh momentum.
Key NPCE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NPCE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.20 | Sell | $16.97 | Buy |
| MA 10 | $16.68 | Buy | $16.73 | Buy |
| MA 20 | $16.17 | Buy | $16.46 | Buy |
| MA 50 | $16.38 | Buy | $16.17 | Buy |
| MA 100 | $15.49 | Buy | $15.72 | Buy |
| MA 200 | $14.74 | Buy | $14.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.24 | Neutral |
| Stoch RSI (14) | 60.58 | Neutral |
| CCI (20) | 103.58 | Buy |
| Williams %R (14) | -28.40 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 7.47 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 71.60 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | 0.96 | Buy |
| Ultimate (7,14,28) | 64.19 | Neutral |
| Momentum (10) | 0.75 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 17.35 | Sell |
| ADX (14) | 12.36 | Neutral |
| ATR (14) | 0.39 | Info |
The near-term technical picture is bullish with a current price of $17.33 trading above both the 50-day simple moving average ($16.36) and the 200-day simple moving average ($14.60). The RSI is at 60, indicating positive momentum. Key levels to watch are support at $15.02 and resistance at $17.39, with the 30-day range spanning from $14.71 to $20.41.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.84 | $17.11 | $22.08 | 0% | Neutral | |
| $17.85 | $22.28 | $29.33 | +30% | Bullish | |
| $22.39 | $28.67 | $39.08 | +68% | Bullish | |
| $27.31 | $35.71 | $50.02 | +109% | Bullish | |
| $32.21 | $42.92 | $61.51 | +151% | Bullish | |
| $34.11 | $46.23 | $67.59 | +170% | Bullish | |
| $37.54 | $51.68 | $76.94 | +202% | Bullish | |
| $42.29 | $59.10 | $89.42 | +245% | Bullish | |
| $47.07 | $66.71 | $102.47 | +290% | Bullish | |
| $60.23 | $86.52 | $134.75 | +406% | Bullish | |
| $86.12 | $131.47 | $217.10 | +668% | Bullish | |
| $162.54 | $275.28 | $495.20 | +15.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.84 | $17.11 | $20.10 | +0.00% |
| August 2026 | $14.44 | $17.01 | $20.55 | -0.58% |
| September 2026 | $14.71 | $17.45 | $21.30 | +2.56% |
| October 2026 | $14.46 | $17.24 | $21.23 | -1.17% |
| November 2026 | $14.20 | $17.01 | $21.10 | -1.36% |
| December 2026 | $14.70 | $17.68 | $22.08 | +3.96% |
Click any year to see its month-by-month NPCE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NPCE to range from $12.84 to $22.08 through 2026. The $17.11 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NPCE price prediction for 2027 points to an average of $22.28 (low $17.85, high $29.33) — a potential gain of +30% on today's $17.11. Momentum favours further upside here.
In 2028, NPCE is projected to trade between $22.39 and $39.08, averaging $28.67 — a potential gain of +68% from today's $17.11. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
NeuroPace, Inc.'s 2029 outlook centres on $35.71, within a $27.31 to $50.02 range. That is up +25% on the projected 2028 average. That marks a +109% change versus current levels. Momentum favours further upside here.
By 2030, NPCE could reach as high as $61.51, with a base case around $42.92 and support toward $32.21 — roughly +151% from $17.11. Buyers look set to stay in control over this stretch.
Expect NPCE to range from $34.11 to $67.59 through 2031. The $46.23 average target implies a +170% move from current prices. That is up +8% on the projected 2030 average. Momentum favours further upside here.
The NPCE price prediction for 2032 points to an average of $51.68 (low $37.54, high $76.94) — a potential gain of +202% on today's $17.11. Buyers look set to stay in control over this stretch.
In 2033, NPCE is projected to trade between $42.29 and $89.42, averaging $59.10 — a potential gain of +245% from today's $17.11. That is up +14% on the projected 2032 average. Momentum favours further upside here.
NeuroPace, Inc.'s 2034 outlook centres on $66.71, within a $47.07 to $102.47 range. That is up +13% on the projected 2033 average. That marks a +290% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NPCE could reach as high as $134.75, with a base case around $86.52 and support toward $60.23 — roughly +406% from $17.11. Momentum favours further upside here.
Expect NPCE to range from $86.12 to $217.10 through 2040. The $131.47 average target implies a +668% move from current prices. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NPCE price prediction for 2050 points to an average of $275.28 (low $162.54, high $495.20) — a potential gain of +15.1x on today's $17.11. Momentum favours further upside here.
Investing $1,000 in NPCE today (≈ 58.445354 NPCE) could be worth
$16,088.6
+$15,088.6 (+1509%) by 2050 · US Dollar
Based on the average projected NPCE price of $275.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NPCEwould be worth at today's price.
$1,000 invested in NPCE on Jul 10, 2025 (≈ 98.328416 NPCE) would be worth
$1,682.4
+$682.4 (+68.2%) today · 1.68× · US Dollar
Based on a NPCE entry price of $10.17 vs. today's $17.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.14 | $1,060.1 | +6.0% |
| 1 month ago | $15.71 | $1,089.12 | +8.9% |
| 3 months ago | $14.26 | $1,199.86 | +20.0% |
| 6 months ago | $16.91 | $1,011.83 | +1.2% |
| 1 year ago | $10.17 | $1,682.4 | +68.2% |
| All time (5.0y) ago | $25.07 | $682.49 | -31.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NPCE forecast.
Our base-case forecast reaches $34.00 around 2029.
Implied market cap at $34.00: $1.16B
Medium- to long-term forecasts show a rising trajectory across the years. The 2026 forecast centers around an average of $17.33 (min $12.84, max $22.49) with a neutral sentiment and 0% ROI, suggesting values near the current price in the near term. By 2027 the average price is projected at $22.30 (min $17.90, max $29.31) with a 28.7% ROI and bullish sentiment.
The path continues higher through 2028 ($28.54 avg, 64.7% ROI), 2029 ($35.43 avg, 104.5% ROI), and 2030 ($42.10 avg, 142.9% ROI), all labeled bullish. The forecast extends to 2031 ($45.46 avg, 162.3% ROI), 2032 ($50.66 avg, 192.3% ROI), 2033 ($57.21 avg, 230.1% ROI), 2034 ($64.73 avg, 273.5% ROI), and 2035 ($83.74 avg, 383.2% ROI), all bullish. In the far horizon, 2040 shows $125.21 avg with a 622.5% ROI, and 2050 shows $261.68 avg with a 1410% ROI, both bullish.
These figures illustrate a strong long-term upside with increasing maxima, though they are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast gives an average of $42.10, a min of $31.69, and a max of $60.11 with a projected ROI of 142.9% and bullish sentiment.
The forecast shows bullish sentiment starting in 2027 and continuing through 2035 and beyond, with rising average prices and higher maximums. For 2026 the average is $17.33 (ROI 0) and sentiment neutral, then turning bullish in subsequent years.
Yes. The forecast shows a max of $129.77 in 2035 and higher maxima thereafter, with 2040 max $205.53 and 2050 max $467.35, indicating potential to exceed $100 in the longer term.
Current price is $17.33 and market cap is $590.84M.
The 30-day range is from $14.71 to $20.41, with a current price of $17.33, support at $15.02, resistance at $17.39, RSI 14 at 60, and a bullish overall sentiment.
NeuroPace, Inc. Community Discussion
0Share your NeuroPace, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.